US challenges 'bogus' patents on Ozempic and other drugs in effort to spur competition
Release time：2024-05-22 04:04:41 Source：Culture Capsule news portal
WASHINGTON (AP) — Federal regulators are challenging patents on 20 brand name drugs, including the blockbuster weight-loss injection Ozempic, in the latest action by the Biden administration targeting industry practices that drive up pharmaceutical prices.
The Federal Trade Commission on Tuesday sent warning letters to 10 drugmakers, taking issue with patents on popular drugs for weight loss, diabetes, asthma and other reparatory conditions. The letters allege that certain patents filed by Novo Nordisk, GlaxoSmithKline, AstraZeneca and seven other companies are inaccurate or misleading.
Brand-name drugmakers use patents to protect their medicines and stave off cheaper, generic medicines. Most blockbuster drugs are protected by dozens of patents covering various ingredients, manufacturing processes and intellectual property. Generic drugmakers can only launch their own cheaper versions if the patents have expired or are successfully challenged in court.
- Previous：Kristin Cavallari, 37, ignores critics of her age
- Next：Analysis: Larson enters conversation with Verstappen as best drivers in the world
Related articles
- Georgia Republicans choose Amy Kremer, organizer of pro
- NPC aims to further enhance the legal system
- Chairman of Foreign Affairs Committee named NPC spokesman
- 2023 Zhejiang Agricultural Expo showcased about 14,000 types of agricultural products
- Minnesota Equal Rights Amendment fails in acrimonious end to legislative session
- Procuratorates advance public interest litigation
- Russia summons German diplomat over leaked tape
- Xi greets Sharif on election as Pakistani PM
- Queen Camilla reveals she's seen the first season of Bridgerton
- NPC to review draft that clarifies nature, status of State Council
- Supreme Court declines to hear challenge to Maryland ban on rifles known as assault weapons
- Envoy hails new height of China
- Spirit of the Silk Road lives on in Xi'an
- The northern section of Beijing Subway Line 17 will open by the end of the year
- OpenAI pauses ChatGPT voice after Scarlett Johansson comparisons
- Xi attends opening meeting of NPC annual session
- Wang: China addresses hotspot issues through the Chinese way
- First volume of 'Xi Jinping: The Governance of China' published in Bulgarian
- Arrest Lord Mountbatten's self
- European leaders hit back at Macron remark
Random recommendation
- Copyright © 2024 Powered by US challenges 'bogus' patents on Ozempic and other drugs in effort to spur competition ,Culture Capsule news portal sitemap